CoChat
Sign Up
Cited by 53

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment

Grabek, Julian, Straube, Jasmin, Bywater, Megan, Lane, Steven W.·2020·Cells
DOI 10.3390/cells9081901PMC PMC7465511
Open this paper in CoChat — free account

Abstract

Myeloproliferative neoplasms (MPNs) constitute a group of disorders identified by an overproduction of cells derived from myeloid lineage. The majority of MPNs have an identifiable driver mutation responsible for cytokine-independent proliferative signalling. The acquisition of coexisting mutations in chromatin modifiers, spliceosome complex components, DNA methylation modifiers, tumour suppressors and transcriptional regulators have been identified as major pathways for disease progression and leukemic transformation. They also confer different sensitivities to therapeutic options. This review will explore the molecular basis of MPN pathogenesis and specifically examine the impact of coexisting mutations on disease biology and therapeutic options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells9081901

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Adapted from [17] showing the frequency of each driver mutation in Myeloproliferative neoplasms (MPN) relative to the disease phenotype.
Figure 1 Adapted from [17] showing the frequency of each driver mutation in Myeloproliferative neoplasms (MPN) relative to the disease phenotype.CC BY · PubMed Central
Figure 2 The molecular signalling pathways involved in MPN: The cell surface receptors are erythropoietin receptor (EPOR; red) and thrombopoietin receptor/MPL (navy blue), MPL with mutated Calreticulin (CALR), wildtype MPL with no ligand (thrombopoietin (TPO)) bound and no STAT signalling, wildtype EPOR with bound ligand (erythropoietin (EPO)) leading to STAT signalling, EPOR with JAK2 mutant, MPL with JAK2 mutant and mutated MPL. The cytoplasm shows STAT pathway signalling with activation of phosphatidylinositol 3-kinase (PI3K)/Akt and RAS pathways, and the nucleus (lilac background) shows the effects of driver and coexisting mutations on nuclear functions. Headings for DNA methylation modifiers, tumour suppressors, transcription regulators, spliceosome complex and chromatin modification identify the key sites of coexisting mutations. Abbreviations not mentioned in the body of the article: STAT, signal transducers and activators of transcription; PI3K, phosphatidylinositol 3-kinase; Akt, Protein kinase B; mTOR, mammalian target of rapamycin; SUZ12, suppressor of zeste 12 homolog; EEZ, embryonic ectoderm development; BAP1, BRCA1-associated protein 1; BRD4, bromodomain containing protein 4; BCL-2, B cell lymphoma 2; BCL-XL, B cell lymphoma extra large; Ac, acetylated; Me, methylated; Ub, ubiquitinated; P, phosphorylated; mut, mutated.
Figure 2 The molecular signalling pathways involved in MPN: The cell surface receptors are erythropoietin receptor (EPOR; red) and thrombopoietin receptor/MPL (navy blue), MPL with mutated Calreticulin (CALR), wildtype MPL with no ligand (thrombopoietin (TPO)) bound and no STAT signalling, wildtype EPOR with bound ligand (erythropoietin (EPO)) leading to STAT signalling, EPOR with JAK2 mutant, MPL with JAK2 mutant and mutated MPL. The cytoplasm shows STAT pathway signalling with activation of phosphatidylinositol 3-kinase (PI3K)/Akt and RAS pathways, and the nucleus (lilac background) shows the effects of driver and coexisting mutations on nuclear functions. Headings for DNA methylation modifiers, tumour suppressors, transcription regulators, spliceosome complex and chromatin modification identify the key sites of coexisting mutations. Abbreviations not mentioned in the body of the article: STAT, signal transducers and activators of transcription; PI3K, phosphatidylinositol 3-kinase; Akt, Protein kinase B; mTOR, mammalian target of rapamycin; SUZ12, suppressor of zeste 12 homolog; EEZ, embryonic ectoderm development; BAP1, BRCA1-associated protein 1; BRD4, bromodomain containing protein 4; BCL-2, B cell lymphoma 2; BCL-XL, B cell lymphoma extra large; Ac, acetylated; Me, methylated; Ub, ubiquitinated; P, phosphorylated; mut, mutated.CC BY · PubMed Central
Figure 3 A proposed model for clonal evolution in MPN with acquisition of additional mutations leading to disease progression.
Figure 3 A proposed model for clonal evolution in MPN with acquisition of additional mutations leading to disease progression.CC BY · PubMed Central
Figure 4 Treatments in MPN and the mechanism of action to control the disease through DNA damage, signalling and proliferation and cell cycle and self-renewal effects: Toxic symbol, chemotherapeutic agents; JAKi, JAK inhibitor; IRF9, interferon regulatory factor 9; ISGs, interferon-stimulated genes; TYK2, tyrosine kinase 2.
Figure 4 Treatments in MPN and the mechanism of action to control the disease through DNA damage, signalling and proliferation and cell cycle and self-renewal effects: Toxic symbol, chemotherapeutic agents; JAKi, JAK inhibitor; IRF9, interferon regulatory factor 9; ISGs, interferon-stimulated genes; TYK2, tyrosine kinase 2.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 195

  1. Heppner, J., Nguyen, L.T., Guo, M., Naugler, C., and Rashid-Kolvear, F. (2019). Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. BMC Res. Notes, 12. · DOI
  2. Cerquozzi, 2015, Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: A literature review of incidence and risk factors, Blood Cancer J., 5, e366, 10.1038/bcj.2015.95 · DOI
  3. Tefferi, 2013, Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study, Leukemia, 27, 1874, 10.1038/leu.2013.163 · DOI
  4. Vannucchi, 2007, Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden, Leukemia, 21, 1952, 10.1038/sj.leu.2404854 · DOI
  5. Barbui, 2016, The effect of arterial hypertension on thrombosis in low-risk polycythemia vera, Am. J. Hematol., 92, E5
  6. Tefferi, 2016, Targeted deep sequencing in polycythemia vera and essential thrombocythemia, Blood Adv., 1, 21, 10.1182/bloodadvances.2016000216 · DOI
  7. Vannucchi, 2018, Polycythemia vera and essential thrombocythemia, Curr. Opin. Hematol., 25, 112, 10.1097/MOH.0000000000000402 · DOI
  8. Tefferi, 2020, Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera, Br. J. Haematol., 189, 291, 10.1111/bjh.16380 · DOI
  9. Barbui, 2012, Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis), Blood, 120, 5128, 10.1182/blood-2012-07-444067 · DOI
  10. Passamonti, 2010, A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment), Blood, 115, 1703, 10.1182/blood-2009-09-245837 · DOI
  11. Gangat, N., and Tefferi, A. (2020). Myelofibrosis biology and contemporary management. Br. J. Haematol. · DOI
  12. Ciboddo, 2018, JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy, Hematol., 2018, 110, 10.1182/asheducation-2018.1.110 · DOI
  13. Gowin, 2016, Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis, Haematol., 101, e405, 10.3324/haematol.2016.149013 · DOI
  14. Passamonti, 2017, A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis, Leukemia, 31, 2726, 10.1038/leu.2017.169 · DOI
  15. Grinfeld, 2018, Classification and Personalized Prognosis in Myeloproliferative Neoplasms, N. Engl. J. Med., 379, 1416, 10.1056/NEJMoa1716614 · DOI
  16. Prins, 2020, Mutant Calreticulin in the Myeloproliferative Neoplasms, HemaSphere, 4, e333, 10.1097/HS9.0000000000000333 · DOI
  17. Gnanasambandan, 2011, A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: The road not taken, Curr. Med. Chem., 18, 4659, 10.2174/092986711797379267 · DOI
  18. Saharinen, 2000, Regulation of the Jak2 tyrosine kinase by its pseudokinase domain, Mol. Cell. Biol., 20, 3387, 10.1128/MCB.20.10.3387-3395.2000 · DOI
  19. Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023 · DOI · Paper page
  20. Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet Lond. Engl. J., 365, 1054, 10.1016/S0140-6736(05)71142-9 · DOI · Paper page
  21. James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, 434, 1144, 10.1038/nature03546 · DOI
  22. Kralovics, 2005, A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders, N. Engl. J. Med., 352, 1779, 10.1056/NEJMoa051113 · DOI · Paper page
  23. Levine, 2007, Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders, Nat. Rev. Cancer, 7, 673, 10.1038/nrc2210 · DOI
  24. Lu, 2005, Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation, Proc. Natl. Acad. Sci. USA, 102, 18962, 10.1073/pnas.0509714102 · DOI
  25. Rivat, 2006, Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells, Blood, 108, 1551, 10.1182/blood-2005-10-009514 · DOI
  26. Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747 · DOI · Paper page
  27. Cordua, 2019, Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population, Blood, 134, 469, 10.1182/blood.2019001113 · DOI
  28. Mansier, 2019, Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells, Blood, 134, 2383, 10.1182/blood.2019001163 · DOI
  29. Rumi, 2014, JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes, Blood, 123, 1544, 10.1182/blood-2013-11-539098 · DOI
  30. Kralovics, 2002, Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera, Exp. Hematol., 30, 229, 10.1016/S0301-472X(01)00789-5 · DOI
  31. Xing, 2008, Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice, Blood, 111, 5109, 10.1182/blood-2007-05-091579 · DOI
  32. Saliba, J., Hamidi, S., Lenglet, G., Langlois, T., Yin, J., Cabagnols, X., Secardin, L., Legrand, C., Galy, A., and Opolon, P. (2013). Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. PLoS ONE, 8. · DOI
  33. Vannucchi, 2007, Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia, Blood, 110, 840, 10.1182/blood-2006-12-064287 · DOI
  34. Godfrey, 2012, JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone, Blood, 120, 2704, 10.1182/blood-2012-05-431791 · DOI
  35. Chen, 2010, Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling, Cancer Cell, 18, 524, 10.1016/j.ccr.2010.10.013 · DOI
  36. Duek, 2014, Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F–driven mouse model of MPNs, Blood, 123, 3943, 10.1182/blood-2013-07-514208 · DOI
  37. Skoda, 2015, Pathogenesis of myeloproliferative neoplasms, Exp. Hematol., 43, 599, 10.1016/j.exphem.2015.06.007 · DOI
  38. Grisouard, 2015, Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN, Blood, 125, 2131, 10.1182/blood-2014-08-594572 · DOI
  39. Yan, 2012, Critical requirement for Stat5 in a mouse model of polycythemia vera, Blood, 119, 3539, 10.1182/blood-2011-03-345215 · DOI
  40. Kleppe, 2015, JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response, Cancer Discov., 5, 316, 10.1158/2159-8290.CD-14-0736 · DOI
  41. Panteli, 2005, Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases, Br. J. Haematol., 130, 709, 10.1111/j.1365-2141.2005.05674.x · DOI
  42. Gilles, 2017, Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis, J. Clin. Investig., 127, 1316, 10.1172/JCI82905 · DOI
  43. Abbonante, 2016, Thrombopoietin/TGF-β1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis, Stem Cells, 34, 1123, 10.1002/stem.2285 · DOI
  44. Malara, 2014, Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin, Stem Cells, 32, 926, 10.1002/stem.1626 · DOI
  45. Scott, 2007, JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis, N. Engl. J. Med., 356, 459, 10.1056/NEJMoa065202 · DOI
  46. Gold, 2009, Calreticulin: Non-endoplasmic reticulum functions in physiology and disease, FASEB J., 24, 665, 10.1096/fj.09-145482 · DOI
  47. Gardai, 2005, Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte, Cell, 123, 321, 10.1016/j.cell.2005.08.032 · DOI · Paper page
  48. Elf, 2016, Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation, Cancer Discov., 6, 368, 10.1158/2159-8290.CD-15-1434 · DOI · Paper page
  49. Pecquet, 2019, Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants, Blood, 133, 2669, 10.1182/blood-2018-09-874578 · DOI
  50. Masubuchi, 2019, Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface, Leukemia, 34, 499, 10.1038/s41375-019-0564-z · DOI
  51. Araki, 2018, Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation, Leukemia, 33, 122, 10.1038/s41375-018-0181-2 · DOI
  52. Chachoua, 2016, Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants, Blood, 127, 1325, 10.1182/blood-2015-11-681932 · DOI
  53. How, 2019, Mutant calreticulin in myeloproliferative neoplasms, Blood, 134, 2242, 10.1182/blood.2019000622 · DOI
  54. Pietra, 2016, Faculty Opinions recommendation of Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms, Fac. Opin. Post-Publ. Peer Rev. Biomed. Lit., 30, 431
  55. Angona, 2016, Characterization of CD34+ hematopoietic progenitor cells in JAK2 V617F and CALR -mutated myeloproliferative neoplasms, Leuk. Res., 48, 11, 10.1016/j.leukres.2016.06.009 · DOI
  56. Lasho, 2018, Targeted next-generation sequencing in blast phase myeloproliferative neoplasms, Blood Adv., 2, 370, 10.1182/bloodadvances.2018015875 · DOI
  57. McNamara, 2018, The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes, Blood Adv., 2, 2658, 10.1182/bloodadvances.2018021469 · DOI
  58. Venton, 2017, Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms, Am. J. Hematol., 93, 330, 10.1002/ajh.24973 · DOI
  59. Courtier, 2019, Targeted molecular characterization shows differences between primary and secondary myelofibrosis, Geneschromosom. Cancer, 59, 30, 10.1002/gcc.22789 · DOI
  60. Pardanani, 2006, MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients, Blood, 108, 3472, 10.1182/blood-2006-04-018879 · DOI
  61. Mead, 2017, Myeloproliferative neoplasm stem cells, Blood, 129, 1607, 10.1182/blood-2016-10-696005 · DOI · Paper page
  62. Vainchenker, 2017, Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms, Blood, 129, 667, 10.1182/blood-2016-10-695940 · DOI · Paper page
  63. Pawlikowska, 2013, Thrombopoietin-Increased DNA-PK-Dependent DNA Repair Limits Hematopoietic Stem and Progenitor Cell Mutagenesis in Response to DNA Damage, Cell Stem Cell, 12, 37, 10.1016/j.stem.2012.10.012 · DOI
  64. Guenther, 2019, Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells, Exp. Hematol., 73, 1, 10.1016/j.exphem.2019.03.002 · DOI
  65. Barbieri, 2018, Thrombopoietin protects hematopoietic stem cells from retrotransposon-mediated damage by promoting an antiviral response, J. Exp. Med., 215, 1463, 10.1084/jem.20170997 · DOI
  66. Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med., 3. · DOI
  67. Defour, 2015, Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: Implications for myeloproliferative neoplasms, Leukemia, 30, 1214, 10.1038/leu.2015.271 · DOI
  68. Rumi, 2013, Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms, Blood, 121, 4388, 10.1182/blood-2013-02-486050 · DOI
  69. Pecquet, 2012, Thrombopoietin receptor down-modulation by JAK2 V617F: Restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes, Blood, 119, 4625, 10.1182/blood-2011-08-372524 · DOI
  70. Maifrede, 2017, Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms, Blood, 130, 2848, 10.1182/blood-2017-05-784942 · DOI
  71. Alexander, 1996, Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl, Blood, 87, 2162, 10.1182/blood.V87.6.2162.bloodjournal8762162 · DOI
  72. Alexander, 1996, Studies of the c‐Mpl Thrombopoietin Receptor through Gene Disruption and Activation, Stem Cells, 14, 124, 10.1002/stem.5530140716 · DOI
  73. Tiedt, 2009, Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes, Blood, 113, 1768, 10.1182/blood-2008-03-146084 · DOI
  74. Lannutti, 2009, Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis, Blood, 113, 1778, 10.1182/blood-2007-11-124859 · DOI
  75. Feenstra, 2016, Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms, Blood, 127, 325, 10.1182/blood-2015-07-661835 · DOI
  76. Cabagnols, 2016, Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients, Blood, 127, 333, 10.1182/blood-2015-07-661983 · DOI
  77. Tefferi, 2018, Myelofibrosis Treatment Algorithm 2018, Blood Cancer J., 8, 72, 10.1038/s41408-018-0109-0 · DOI
  78. Yang, 2018, Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies, Blood, 131, 328, 10.1182/blood-2017-06-789669 · DOI
  79. Trouplin, 2009, Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia, Br. J. Haematol., 145, 788, 10.1111/j.1365-2141.2009.07697.x · DOI
  80. Adli, 2012, ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression, Cancer Cell, 22, 180, 10.1016/j.ccr.2012.06.032 · DOI
  81. Scheuermann, 2010, Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB, Nature, 465, 243, 10.1038/nature08966 · DOI · Paper page
  82. Balasubramani, 2015, Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex, Nat. Commun., 6, 7307, 10.1038/ncomms8307 · DOI · Paper page
  83. Asada, 2018, Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis, Nat. Commun., 9, 2733, 10.1038/s41467-018-05085-9 · DOI
  84. Kitamura, 2018, ASXL1 mutations gain a function, Blood, 131, 274, 10.1182/blood-2017-12-816595 · DOI
  85. Score, 2012, Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms, Blood, 119, 1208, 10.1182/blood-2011-07-367243 · DOI · Paper page
  86. Li, 2019, EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implications, J. Hematol. Oncol., 12, 118, 10.1186/s13045-019-0814-6 · DOI
  87. Popovic, 2013, EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation, Cancer Cell, 23, 677, 10.1016/j.ccr.2013.04.011 · DOI
  88. Saunthararajah, 2012, Polycomb segment myeloid malignancies, Blood, 119, 1097, 10.1182/blood-2011-12-391268 · DOI · Paper page
  89. Velcheti, 2019, EZH2 Inhibitors: Take It EZy, It Is All About Context, Cancer Discov., 9, 472, 10.1158/2159-8290.CD-19-0090 · DOI
  90. Yang, 2016, Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm, Blood, 127, 3410, 10.1182/blood-2015-11-679431 · DOI
  91. Shimizu, 2016, Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis, J. Exp. Med., 213, 1479, 10.1084/jem.20151136 · DOI
  92. Guglielmelli, 2011, EZH2 mutational status predicts poor survival in myelofibrosis, Blood, 118, 5227, 10.1182/blood-2011-06-363424 · DOI
  93. Komeno, 2015, SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing, Mol. Cell. Boil., 35, 3071, 10.1128/MCB.00202-15 · DOI
  94. Smeets, 2018, Srsf2 P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells, Blood, 132, 608, 10.1182/blood-2018-04-845602 · DOI
  95. Liu, Y.-C., Illar, G.M., and Bailey, N.G. (2020). Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations. J. Clin. Pathol., 1–9. · DOI
  96. Soares, 2006, Intron removal requires proofreading of U2AF/3′ splice site recognition by DEK, Science, 312, 1961, 10.1126/science.1128659 · DOI
  97. Graubert, 2011, Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes, Nat. Genet., 44, 53, 10.1038/ng.1031 · DOI
  98. Isono, 2005, Mammalian Polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1, Genes Dev., 19, 536, 10.1101/gad.1284605 · DOI
  99. Cazzola, 2013, Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms, Blood, 121, 260, 10.1182/blood-2012-09-399725 · DOI
  100. Lasho, 2011, SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients, Leukemia, 26, 1135, 10.1038/leu.2011.320 · DOI
  101. Schischlik, 2019, Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms, Blood, 134, 199, 10.1182/blood.2019000519 · DOI
  102. Shih, 2012, The role of mutations in epigenetic regulators in myeloid malignancies, Nat. Rev. Cancer, 12, 599, 10.1038/nrc3343 · DOI · Paper page
  103. Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes, N. Engl. J. Med., 371, 2488, 10.1056/NEJMoa1408617 · DOI · Paper page
  104. Anteneh, 2020, Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation, Nat. Commun., 11, 2294, 10.1038/s41467-020-16213-9 · DOI
  105. Jacquelin, 2018, Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation, Blood, 132, 2707, 10.1182/blood-2018-04-846220 · DOI · Paper page
  106. Mullally, 2009, Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies, Blood, 114, 144, 10.1182/blood-2009-03-210039 · DOI · Paper page
  107. Ostrander, 2020, Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness, Stem Cell Rep., 14, 551, 10.1016/j.stemcr.2020.02.011 · DOI · Paper page
  108. Lundberg, 2014, Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, 123, 2220, 10.1182/blood-2013-11-537167 · DOI
  109. Ortmann, 2015, Effect of mutation order on myeloproliferative neoplasms, N. Engl. J. Med., 372, 601, 10.1056/NEJMoa1412098 · DOI · Paper page
  110. Nekrutenko, 1998, Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family, Mol. Boil. Evol., 15, 1674, 10.1093/oxfordjournals.molbev.a025894 · DOI
  111. Park, 2008, Inactivation of mitochondrial NADP+-dependent isocitrate dehydrogenase by hypochlorous acid, Free. Radic. Res., 42, 467, 10.1080/10715760802098834 · DOI
  112. Tefferi, 2010, IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis, Leukemia, 24, 1302, 10.1038/leu.2010.113 · DOI
  113. Pardanani, 2010, IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms, Leukemia, 24, 1146, 10.1038/leu.2010.77 · DOI
  114. Delic, 2016, Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera, Br. J. Haematol., 175, 419, 10.1111/bjh.14269 · DOI
  115. McKenney, 2018, JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition, J. Clin. Investig., 128, 789, 10.1172/JCI94516 · DOI
  116. Yoshimi, 2019, Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis, Nature, 574, 273, 10.1038/s41586-019-1618-0 · DOI
  117. Kubesova, 2017, Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: Association with age, hydroxyurea administration, disease type and JAK2 mutational status, Leukemia, 32, 450, 10.1038/leu.2017.230 · DOI · Paper page
  118. Zhang, 2012, Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome, Blood, 119, 4480, 10.1182/blood-2011-11-390252 · DOI
  119. Marcellino, 2018, Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53, Blood Adv., 2, 3581, 10.1182/bloodadvances.2018024018 · DOI
  120. Harutyunyan, 2011, p53 Lesions in Leukemic Transformation, N. Engl. J. Med., 364, 488, 10.1056/NEJMc1012718 · DOI
  121. Koya, 2017, Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera, Oncogene, 36, 3300, 10.1038/onc.2016.478 · DOI · Paper page
  122. Rampal, 2014, Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms, Proc. Natl. Acad. Sci. USA, 111, E5401, 10.1073/pnas.1407792111 · DOI · Paper page
  123. Sood, 2017, Role of RUNX1 in hematological malignancies, Blood, 129, 2070, 10.1182/blood-2016-10-687830 · DOI
  124. Guglielmelli, 2019, Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs), Blood, 134, 2968, 10.1182/blood-2019-129094 · DOI
  125. Bujak, 2009, Hydroxyurea and hydroxamic acid derivatives as antitumor drugs, Cancer Chemother. Pharmacol., 64, 213, 10.1007/s00280-009-0991-z · DOI
  126. Fruchtman, 1997, From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera, Semin. Hematol., 34, 17
  127. Cortelazzo, 1995, Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis, N. Engl. J. Med., 332, 1132, 10.1056/NEJM199504273321704 · DOI
  128. Gaya, 2010, Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients, Ann. Hematol., 89, 1233, 10.1007/s00277-010-1019-9 · DOI
  129. Yacoub, 2019, Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings, Blood, 134, 2943, 10.1182/blood-2019-124865 · DOI
  130. Finazzi, 2005, Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study, Blood, 105, 2664, 10.1182/blood-2004-09-3426 · DOI
  131. Nand, 1996, Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Am. J. Hematol., 52, 42, 10.1002/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6 · DOI
  132. Gisslinger, 2020, Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study, Lancet Haematol., 7, e196, 10.1016/S2352-3026(19)30236-4 · DOI
  133. Antelo, 2014, Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea, Ann. Hematol., 93, 2037, 10.1007/s00277-014-2152-7 · DOI
  134. Shvidel, 2007, Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia, Leukemia, 21, 2071, 10.1038/sj.leu.2404743 · DOI
  135. Fang, 2019, p53 mediates hydroxyurea resistance in aneuploid cells of colon cancer, Exp. Cell Res., 376, 39, 10.1016/j.yexcr.2019.01.013 · DOI
  136. Harrison, 2012, JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis, N. Engl. J. Med., 366, 787, 10.1056/NEJMoa1110556 · DOI · Paper page
  137. Verstovsek, 2010, Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis, N. Engl. J. Med., 363, 1117, 10.1056/NEJMoa1002028 · DOI
  138. Andraos, 2012, Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent, Cancer Discov., 2, 512, 10.1158/2159-8290.CD-11-0324 · DOI
  139. Tvorogov, 2018, Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis, Sci. Adv., 4, eaat3834, 10.1126/sciadv.aat3834 · DOI
  140. Koppikar, 2012, Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy, Nature, 489, 155, 10.1038/nature11303 · DOI
  141. Meyer, 2014, Molecular pathways: Molecular basis for sensitivity and resistance to JAK kinase inhibitors, Clin. Cancer Res., 20, 2051, 10.1158/1078-0432.CCR-13-0279 · DOI
  142. Singer, J.W., Al-Fayoumi, S., Taylor, J., Velichko, S., and O’Mahony, A. (2019). Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLoS ONE, 14. · DOI
  143. Zhang, 2018, Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia, Oncotarget, 9, 8027, 10.18632/oncotarget.24261 · DOI
  144. Kong, 2017, How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study, Sci. Rep., 7, 1, 10.1038/s41598-017-09586-3 · DOI
  145. Verstovsek, 2017, Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses, J. Hematol. Oncol., 10, 156, 10.1186/s13045-017-0527-7 · DOI · Paper page
  146. Vannucchi, 2015, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, N. Engl. J. Med., 372, 426, 10.1056/NEJMoa1409002 · DOI · Paper page
  147. Verstovsek, 2016, Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial, Haematologica, 101, 821, 10.3324/haematol.2016.143644 · DOI
  148. Passamonti, 2017, Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study, Lancet Oncol., 18, 88, 10.1016/S1470-2045(16)30558-7 · DOI
  149. Griesshammer, 2018, Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial, Ann. Hematol., 97, 1591, 10.1007/s00277-018-3365-y · DOI
  150. Harrison, 2017, Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide, Blood, 130, 1889, 10.1182/blood-2017-05-785790 · DOI
  151. Verstovsek, 2017, Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: Long-term phase 2 study results, Blood, 130, 1768, 10.1182/blood-2017-02-765032 · DOI
  152. Deininger, 2015, The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis, Blood, 126, 1551, 10.1182/blood-2015-03-635235 · DOI · Paper page
  153. Guglielmelli, 2015, Ruxolitinib is an effective treatment forCALR-positive patients with myelofibrosis, Br. J. Haematol., 173, 938, 10.1111/bjh.13644 · DOI
  154. Vannucchi, 2017, Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study, Ann. Hematol., 96, 1113, 10.1007/s00277-017-2994-x · DOI
  155. Austin, 2019, Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations, Leukemia, 34, 1075, 10.1038/s41375-019-0638-y · DOI · Paper page
  156. Mullally, 2010, Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells, Cancer Cell, 17, 584, 10.1016/j.ccr.2010.05.015 · DOI
  157. Spiegel, 2017, Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy, Blood Adv., 1, 1729, 10.1182/bloodadvances.2017009530 · DOI
  158. Cervantes, 2013, Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis, Blood, 122, 4047, 10.1182/blood-2013-02-485888 · DOI
  159. (2019). Fedratinib Becomes New Option in Myelofibrosis. Cancer Discov., 9, 1332. · DOI
  160. Mullally, 2020, Fedratinib in myelofibrosis, Blood Adv., 4, 1792, 10.1182/bloodadvances.2019000954 · DOI
  161. Pardanani, 2015, Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis, JAMA Oncol., 1, 643, 10.1001/jamaoncol.2015.1590 · DOI
  162. Harrison, 2017, Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study, Lancet Haematol., 4, e317, 10.1016/S2352-3026(17)30088-1 · DOI
  163. Harrison, 2020, Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure, Am. J. Hematol., 95, 594, 10.1002/ajh.25777 · DOI
  164. Mesa, 2017, SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis, J. Clin. Oncol., 35, 3844, 10.1200/JCO.2017.73.4418 · DOI
  165. Harrison, 2018, Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial, Lancet Haematol., 5, e73, 10.1016/S2352-3026(17)30237-5 · DOI
  166. Asshoff, 2017, Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents, Blood, 129, 1823, 10.1182/blood-2016-09-740092 · DOI
  167. Tefferi, 2018, Momelotinib therapy for myelofibrosis: A 7-year follow-up, Blood Cancer J., 8, 1, 10.1038/s41408-018-0067-6 · DOI
  168. Singer, 2016, Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor, J. Exp. Pharmacol., 8, 11, 10.2147/JEP.S110702 · DOI
  169. Mesa, 2017, Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial, Lancet Haematol., 4, e225, 10.1016/S2352-3026(17)30027-3 · DOI
  170. Mascarenhas, 2018, Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis, JAMA Oncol., 4, 652, 10.1001/jamaoncol.2017.5818 · DOI
  171. Diaz, 2018, Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia, Future Oncol., 14, 797, 10.2217/fon-2017-0494 · DOI
  172. Bellucci, 1988, Treatment of essential thrombocythaemia by alpha 2a interferon, Lancet, 332, 960, 10.1016/S0140-6736(88)92625-6 · DOI
  173. Green, 2018, Interferon-stimulated genes: New platforms and computational approaches, Mamm. Genome, 29, 593, 10.1007/s00335-018-9755-6 · DOI
  174. Raftery, 2017, Advances in anti-viral immune defence: Revealing the importance of the IFN JAK/STAT pathway, Cell. Mol. Life Sci., 74, 2525, 10.1007/s00018-017-2520-2 · DOI
  175. Walter, 2015, Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells, Nature, 520, 549, 10.1038/nature14131 · DOI · Paper page
  176. Sato, 2009, Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion, Nat. Med., 15, 696, 10.1038/nm.1973 · DOI
  177. Mullally, 2013, Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera, Blood, 121, 3692, 10.1182/blood-2012-05-432989 · DOI
  178. Hasan, 2013, JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα, Blood, 122, 1464, 10.1182/blood-2013-04-498956 · DOI
  179. Kiladjian, 2008, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, 112, 3065, 10.1182/blood-2008-03-143537 · DOI
  180. Kantarjian, 2009, Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera, J. Clin. Oncol., 27, 5418, 10.1200/JCO.2009.23.6075 · DOI
  181. Ianotto, 2017, Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: A French Intergroup of Myeloproliferative neoplasms (FIM) study, Haematologica, 103, 438, 10.3324/haematol.2017.181297 · DOI
  182. Manshouri, 2013, Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a, Blood, 122, 893, 10.1182/blood-2012-07-442012 · DOI
  183. Verger, 2015, Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations, Blood, 126, 2585, 10.1182/blood-2015-07-659060 · DOI
  184. Mikkelsen, 2018, Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis, Cancer Med., 7, 3571, 10.1002/cam4.1619 · DOI
  185. Carreras, E., Dufour, C., Mohty, M., and Kröger, N. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer. · DOI
  186. Deeg, 2015, Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT/ELN international working group, Leukemia, 29, 2126, 10.1038/leu.2015.233 · DOI
  187. Robin, 2019, Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis, Haematologica, 104, 1782, 10.3324/haematol.2018.205211 · DOI
  188. Gowin, 2020, Survival following allogeneic transplant in patients with myelofibrosis, Blood Adv., 4, 1965, 10.1182/bloodadvances.2019001084 · DOI
  189. Tamari, 2019, Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis, Boil. Blood Marrow Transplant., 25, 1142, 10.1016/j.bbmt.2019.01.002 · DOI
  190. Devlin, 2016, Myelofibrosis: To transplant or not to transplant?, Hematology, 2016, 543, 10.1182/asheducation-2016.1.543 · DOI
  191. Prestipino, 2018, Oncogenic JAK2V617Fcauses PD-L1 expression, mediating immune escape in myeloproliferative neoplasms, Sci. Transl. Med., 10, eaam7729, 10.1126/scitranslmed.aam7729 · DOI
  192. Ahmad, 2016, The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms, Leukemia, 31, 495
  193. Martinenaite, 2017, The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy, Leukemia, 32, 429
  194. Schieber, 2019, Myelofibrosis in 2019: Moving beyond JAK2 inhibition, Blood Cancerj., 9, 74, 10.1038/s41408-019-0236-2 · DOI
  195. Vannucchi, 2017, Emerging treatments for classical myeloproliferative neoplasms, Blood, 129, 693, 10.1182/blood-2016-10-695965 · DOI

Cited by

See all 53

Metadata

Authors
Grabek, J., Straube, J., Bywater, M., & Lane, S. W.
Venue
Cells
Publisher
MDPI AG
Published
2020-08-14
Volume
9
Issue
8
Pages
1901
ISSN
2073-4409
DOI
10.3390/cells9081901
PMC
PMC7465511
Cited by
53
References
17
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review